Insider trade

CEO sold ~$184K of KRYS shares in the open market

Traded Sep 4, 2026 · Filed Sep 4, 2026

Why it stands out

The boss of Krystal Biotech sold $184K of Krystal Biotech shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$184,361

Shares × reported transaction price

Timing vs results

32 days after results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−4.2%	−1.1%	−3.0%

Past results only. Not a forecast.

The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.